CAP-Ketamine for Antidepressant Resistant PTSD

Completed · Phase 2 · Has a placebo group

Conditions studied: PTSD, Posttraumatic Stress Disorder

In brief

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.

Key facts

Study ID

NCT02655692

Run by

VA Office of Research and Development

People needed

163

Starts

2016-04-18

Expected to finish

2020-07-01

Last updated by the study team

2022-06-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• male or female Veterans or active duty military personnel between the ages of 18 and 70 years
• diagnosis of PTSD
• history of trialing one or more antidepressant medications with little to no PTSD symptom improvement
• ability to provide written informed consent

You may not qualify if…

• females who are currently pregnant or breastfeeding
• current high risk for suicide
• history of severe head injury

Where it is running

• VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, Connecticut, United States
• Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, Minnesota, United States
• Brooke Army Medical Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.